Australian Update: Changes to TGA and PBS

TGA is undergoing changes in response to a ‘Functional and Efficiency Review’ of the Department of Health – there is now a ‘Regulatory Service Group’ that includes TGA, the Office of Gene Technology Regulator and the Office of Chemical Safety. There is also a new Regulatory Performance Framework with KPIs that the TGA’s performance will be measured against. The first report is due in the second half of 2016.

How to overcome resistance to biosimilars that are now being listed on the Pharmaceutical Benefits Scheme in order to reap the financial benefits for the taxpayer is an issue for Government. This topic will be addressed as part of a PBS Access and Sustainability Package just announced, with $20 million funding for 2015-18.

by Dr. Richard O. Day, DIA Fellow; DIA Global Forum Regional Editor: Australia/New Zealand; Professor of Clinical Pharmacology, St. Vincent’s Hospital, Australia

Advertisements
This entry was posted in Global Forum. Bookmark the permalink.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s